How is Kalbitor administered?
•
4 min read
According to the FDA, Kalbitor (ecallantide) is approved for the acute treatment of hereditary angioedema (HAE) attacks in patients 12 years and older and carries a boxed warning for anaphylaxis. This significant risk means the question of how is Kalbitor administered has a critical answer: it must be performed by a healthcare professional in a clinical setting.
